Intermittent Explosive Disorder
1
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2024
2025
2026
2027
2028
Acadia PharmaceuticalsPimavanserin 34 mg
Clinical Trials (1)
Total enrollment: 35 patients across 1 trials
Pimavanserin and Aggression and Social Cognition.
Start: Aug 2024Est. completion: Jan 202835 patients
Phase 2Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 35 patients
1 companies competing in this space